ArticleCancer management and research2020
Expression of Zinc Finger and BTB Domain-Containing 4 in Colorectal Cancer and Its Clinical Significance.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- The effects of flavonoid baicalein on miRNA expressions in cancer: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Article
- Transcription Factor Zbtb20 as a Regulator of Malignancy and Its Practical Applications.International journal of molecular sciences · 2023Review
- The Roles of Zinc Finger Proteins in Colorectal Cancer.International journal of molecular sciences · 2023Review
- Identification of ZBTB4 as an immunological biomarker that can inhibit the proliferation and invasion of pancreatic cancer.BMC cancer · 2023Article
- Article
- Comprehensive analysis of key m5C modification-related genes in type 2 diabetes.Frontiers in genetics · 2022Article
- Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.American journal of cancer research · 2022Article
- Adherens junction proteins on the move-From the membrane to the nucleus in intestinal diseases.Frontiers in cell and developmental biology · 2022Review
- Glioma glycolipid metabolism: MSI2-SNORD12B-FIP1L1-ZBTB4 feedback loop as a potential treatment target.Clinical and translational medicine · 2021Article
- Machine-Learning-Based m5C Score for the Prognosis Diagnosis of Osteosarcoma.Journal of oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZinc finger and BTB domain-containing 4 (ZBTB4), which is a transcriptional regulator, has been identified as a tumor suppressor in several human carcinomas. So far, however, the expression of ZBTB4 and its possible clinical significance in colorectal cancer (CRC) remain unknown. MATERIALS AND
methodsThe mRNA and protein expressions of ZBTB4 in five CRC cell lines were respectively detected by performing qRT-PCR and Western Blotting. ZBTB4 expression in colorectal tissue specimens was determined, and subsequently its relationship with clinical prognosis was examined.
resultsThe mRNA and protein expressions of ZBTB4 were significantly decreased in all the five CRC cell lines compared with normal colonic epithelial cells. Consistent with the cell data, immunohistochemical results showed that as compared with the normal colorectal tissue samples, ZBTB4 protein expression was clearly lower in the CRC tissue samples, especially in CRC patients with liver metastasis. In addition, low-expressed ZBTB4 was found associated with tumor metastasis stage (P=0.0003) and level of carcinoembryonic antigen (CEA) (P=0.0004). The overall survival (OS) and recurrence-free survival (RFS) in the ZBTB4-low group were significantly lower than those in the ZBTB4-high group (P=0.0007 and P=0.0077).
conclusionThe current findings showed that patients with high-expressed ZBTB4 in CRC tissues may develop a better prognosis, and ZBTB4 could serve as a potential therapeutic target for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.